Advertisement


James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects

2017 ASTRO Annual Meeting

Advertisement

James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4).



Related Videos

Lung Cancer

Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial

Jeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or without cetuximab for stage III non–small cell lung cancer (Abstract 227).

Lymphoma

Christopher R. Kelsey, MD, on DLBCL: Study Results on Consolidation Radiotherapy

Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II findings show this approach may be effective in light of improved systemic treatment and better chemotherapy response assessment (Presentation 298).

Head and Neck Cancer

Bhishamjit S. Chera, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV-16: Expert Perspective

Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation therapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (Presentation 92).

Prostate Cancer

Tamim Niazi, MDCM, on Prostate Cancer: Results From a Trial on Dose Escalation

Tamim Niazi, MDCM, of McGill University, discusses phase III study findings on hypofractionated, dose-escalation radiation therapy for high-risk adenocarcinoma of the prostate (Abstract 281).

Breast Cancer

Shulian Wang, MD, and Benjamin Movsas, MD, on Breast Cancer: Radiation Therapy After Mastectomy

Shulian Wang, MD, of the National Cancer Center in Beijing, and Benjamin Movsas, MD, of the Henry Ford Health System, discuss study results on the use of hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer (Abstract PL01).

Advertisement

Advertisement




Advertisement